Peapod Lane Capital LLC acquired a new position in Kronos Bio, Inc. (NASDAQ:KRON - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 562,620 shares of the company's stock, valued at approximately $534,000. Peapod Lane Capital LLC owned approximately 0.93% of Kronos Bio as of its most recent filing with the Securities and Exchange Commission.
Separately, Deltec Asset Management LLC bought a new stake in shares of Kronos Bio in the fourth quarter worth approximately $190,000. 64.09% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on KRON. Piper Sandler cut shares of Kronos Bio from an "overweight" rating to a "neutral" rating and dropped their target price for the stock from $6.00 to $1.00 in a report on Thursday, November 14th. TD Cowen cut shares of Kronos Bio from a "buy" rating to a "hold" rating in a research note on Thursday, November 14th.
Read Our Latest Research Report on Kronos Bio
Kronos Bio Price Performance
Shares of NASDAQ KRON remained flat at $1.02 during trading on Monday. The stock had a trading volume of 98,557 shares, compared to its average volume of 216,891. The company has a 50 day simple moving average of $0.99 and a 200 day simple moving average of $0.98. The company has a market capitalization of $61.55 million, a price-to-earnings ratio of -0.71 and a beta of 1.80. Kronos Bio, Inc. has a 1 year low of $0.69 and a 1 year high of $1.60.
About Kronos Bio
(
Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Featured Stories
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
